Dr. Mohammad Awlad Mohammad | Oncology Pharmaceuticals | Research Excellence Award
Al-Quds University | Palestine
Top Featured Publications
Top Featured Publications
Dr. Alexis LeVee at UCLA, United States.
Dr. A. LeVee is a physician-scientist specializing in medical oncology with a focus on breast cancer and translational immunotherapy. Currently a Clinical Instructor at UCLA and a Hematology/Oncology Fellow at City of Hope, Dr. LeVee combines clinical expertise with cutting-edge research in tumor immunology, the microbiome, and novel therapeutic biomarkers. A graduate of Duke University and Tufts Medical School, they are a recipient of multiple national awards, including the ASCO Conquer Cancer Young Investigator Award. With over 10 peer-reviewed publications and leadership in high-impact studies, Dr. LeVee is shaping the future of personalized cancer care and precision immunotherapy.
Publication Profile
Dr. LeVee earned a B.A. in Chemistry with minors in Economics and Biology from Duke University (2013) 🧪, followed by an M.D. from Tufts University School of Medicine (2019) 🩺. They completed an Internal Medicine residency at Cedars-Sinai Medical Center (2019–2022) and are currently completing a Hematology/Medical Oncology Fellowship at City of Hope Comprehensive Cancer Center (2022–2025) 🧠. Their diverse training spans top-tier academic institutions and reflects a deep foundation in both clinical medicine and biomedical sciences, equipping them with the tools to integrate research and practice in complex oncology care.
Dr. LeVee currently serves as Clinical Instructor at UCLA (2025–Present) and Chief Fellow at City of Hope (2023–Present) in the Hematology/Medical Oncology Fellowship Program. Previously, they worked as a Business Analyst at Orange Advisory Group (2013–2015), combining data-driven insight with clinical research. Dr. LeVee has held numerous leadership and committee roles at Cedars-Sinai and City of Hope, contributing to medical education and institutional quality improvement. Their multidisciplinary background and academic leadership experience reflect a strong trajectory toward becoming a leader in translational oncology and academic medicine.
Dr. LeVee has earned multiple prestigious awards, including the Young Investigator Award from ASCO, Conquer Cancer Foundation, and MOASC 🏆. Additional accolades include the Coltman Scholar Award and Early Investigator Award from the San Antonio Breast Cancer Symposium (2024), the ASCO Merit Award (2024), and finalist status for the Rubenstein Award for Resident Research (2022). Earlier honors include fellowships from Tufts, American Thoracic Society, and DukeEngage. These awards reflect their innovative research and impact in oncology, particularly in microbiome science, breast cancer immunotherapy, and biomarker discovery.
Dr. LeVee’s research bridges clinical oncology and translational science, focusing on breast cancer, tumor microenvironment, and immunotherapy 🧬. Their work investigates how microbiota, immune signatures, and biomarkers predict treatment response in triple-negative and HER2+ breast cancers. With funding from ASCO, Biocodex, and City of Hope, Dr. LeVee leads multiple studies analyzing metagenomic and metatranscriptomic profiles of fecal microbiota in patients receiving chemoimmunotherapy. They also explore the cardiotoxic effects of cancer therapies and immuno-radiation synergy. Their goal is to develop precision tools that enhance treatment personalization and patient outcomes in cancer care.
Mrs. Fenghua Wu at Hubei university of chinese medcine, China.
Mrs. Fenghua Wu is a distinguished researcher and educator with a doctoral degree from Tongji Medical College, Huazhong University of Science and Technology 🎓. She specializes in physiology and oncology, focusing on the tumor microenvironment and tumor immunology 🔬. Her groundbreaking research explores the regulatory mechanisms of natural and traditional Chinese medicines in cancer treatment 🌿. As a principal investigator for the National Natural Science Foundation of China, she has published extensively in SCI-indexed journals 📚. Honored as a “Teaching Expert” and COVID-19 frontline contributor 🏅, she also serves as a Guest Editor for Frontiers in Immunology.
Publication Profile
Mrs. Fenghua Wu earned her doctoral degree from Tongji Medical College, Huazhong University of Science and Technology 🏥. She currently teaches physiology and is actively engaged in oncology research 🔬 at her institution. Her work focuses on exploring cancer biology and its treatment mechanisms. As a leading scientist, she has served as the principal investigator for prestigious projects funded by the National Natural Science Foundation of China 🇨🇳. Her academic dedication and scientific contributions reflect her commitment to advancing knowledge in the field of cancer research and education.
Mrs. Fenghua Wu is a proud member of the Chinese Anti-Cancer Association (CACA) 🧬, a prestigious national organization committed to advancing cancer research, treatment, and public health awareness in China 🇨🇳. Her affiliation with CACA underscores her dedication to the oncology field and her active participation in collaborative efforts aimed at combating cancer through scientific innovation and knowledge exchange 🔬. As part of this professional body, she stays connected with leading experts, contributes to cancer-related initiatives, and continuously enhances her expertise to benefit patients and students alike.
Mrs. Fenghua Wu’s research focus lies at the intersection of tumor immunology, traditional Chinese medicine, and molecular oncology 🧬. She explores how natural compounds—such as dihydroartemisinin and capsaicin—can modulate immune responses and inhibit cancer progression, particularly in breast cancer and tongue squamous cell carcinoma (TSCC) 🎯. Her studies often center on critical pathways like TNF-α, PI3K/AKT/mTOR, and TGF-β1, highlighting her commitment to advancing immunotherapy and targeted therapies 🧪. Her category of research can be broadly classified under Cancer Pharmacology, Immuno-Oncology, and Natural Product-Based Therapeutics.
Dr. ATSUSHI HOSUI, Osaka Rosai Hospital, Japan
Dr. Atsushi Hosui, a distinguished hepatologist, earned his M.D. from Osaka University in 1994 🎓. With Japanese Medical License #363021, he holds multiple board certifications in internal medicine, gastroenterology, and hepatology 🏥. Currently serving as Director of Hepatology at Osaka Rosai Hospital, he has led and contributed to numerous clinical trials on NASH, MASH, PBC, and liver cancer 🧬. A member of Japan’s leading medical societies, he is also GCP-trained (2015) 📋. Renowned for his impactful research and over 30 scientific publications, Dr. Hosui is a trailblazer in liver disease therapeutics and pharmaceutical excellence.
Publication Profile
Dr. Atsushi Hosui embarked on his medical journey at the prestigious Osaka University, Japan 🗾, where he earned his Doctor of Medicine (M.D.) degree in March 1994 🎓. Renowned for its excellence in medical education and research, Osaka University provided him with a solid foundation in clinical medicine and scientific inquiry 🧪. His education laid the groundwork for a remarkable career in gastroenterology and hepatology 🏥. Driven by a passion for improving liver health, Dr. Hosui has since become a respected physician, researcher, and clinical investigator, dedicated to advancing pharmaceutical science and patient care globally.
Dr. Atsushi Hosui holds a prestigious Japanese Medical License (#363021) 🇯🇵, validating his long-standing commitment to clinical excellence. He is a board-certified member and specialist of the Japanese Society of Internal Medicine 🧬, where he also serves as an advising doctor 👨⚕️. His specialization extends to gastroenterology and hepatology, holding certified status from the Japanese Society of Gastroenterology 🏥, the Japan Society of Hepatology 🏆, and the Japan Gastroenterological Endoscopy Society 🔬. These recognitions underscore his expertise in digestive health and liver diseases, reflecting a distinguished career devoted to patient care and research innovation.
Dr. Atsushi Hosui has led and contributed to numerous groundbreaking clinical research projects in hepatology and internal medicine 🧬. As an investigator or sub-investigator, he played key roles in studies on NASH (2021–2022) and MASH (2024–2025) 🩺. His focus on hypozincemia (2015), hepatocellular carcinoma (2012–2016), portal vein thrombosis (2015–2016), and PBC (2025–) highlights his expertise in liver-related conditions 🧠. He also contributed significantly to studies on thrombocytopenia and chronic hepatitis C (2013) 🧫. Dr. Hosui’s research dedication reflects his mission to improve liver health and advance pharmaceutical excellence globally.
Dr. Atsushi Hosui’s research is centered around hepatology and gastroenterology, with a strong emphasis on hepatocellular carcinoma (HCC) 🧫, chronic liver diseases 🏥, and vascular complications like gastric varices and Budd-Chiari syndrome 🫀. His clinical investigations span topics such as portal hypertension, black esophagus, hyperglycemic complications, and the long-term risks of hepatitis B treatments 🦠. His innovative approaches combine locoregional therapies, embolization techniques, and pharmacologic interventions to enhance liver cancer outcomes 🎯. Dr. Hosui’s work bridges diagnostic precision with therapeutic advancements in liver-related pathologies, reinforcing his role as a leader in hepatic disease management.
Prof. Dr. Takuma Hayashi, National Hospital Organization Kyoto Medical Center, Japan
Prof. Dr. Takuma Hayashi is a renowned Japanese physician-scientist specializing in gynecologic oncology. 🎓 He earned his PhD from the University of Tokyo and trained at MIT’s Whitehead Institute 🧠, contributing to Nobel-linked research. Currently a professor at Shinshu University and Section Head at Kyoto Medical Center 🏥, his groundbreaking work on uterine leiomyosarcoma (LMS) identified LMP2 deficiency as a key biomarker 🔎. Through precision medicine and genomic profiling 🧬, his research has significantly advanced diagnostics and treatment strategies for LMS. With over 30 years of funded research, Dr. Hayashi is globally recognized for revolutionizing women’s cancer care.
Publication Profile
Prof. Dr. Takuma Hayashi is a distinguished physician-scientist known for bridging fundamental cancer research with clinical applications. 👨⚕️🔬 He is a Professor at Shinshu University Graduate School of Medicine and Section Head at Japan’s National Hospital Organization Kyoto Medical Center. 🎓🏥 Dr. Hayashi earned his PhD from the University of Tokyo and completed postdoctoral training at MIT’s Whitehead Institute under Dr. Rick A. Young. 🎓🇯🇵🇺🇸 He contributed to Nobel Prize-linked AIDS vaccine research with Dr. David Baltimore. With over 30 years of NIH and JSPS funding, his work focuses on molecular research in uterine leiomyosarcoma and ovarian cancer, collaborating with Nobel Laureate Dr. Susumu Tonegawa.
Prof. Dr. Takuma Hayashi has pioneered precision medicine breakthroughs in uterine leiomyosarcoma (LMS) treatment. 🧬💉 His team used cancer genome panel testing to tailor therapies based on each tumor’s unique genetics. For example, immunotherapy with pembrolizumab led to significant tumor regression, while targeted treatment with pazopanib stabilized disease for months. 🎯💊 Dr. Hayashi’s background from the University of Tokyo and MIT supports his innovative approach. 🚀 His ongoing goals include developing diagnostics, launching clinical trials, expanding global collaboration, and improving patient access to genomic profiling. 🌍💡 His work offers new hope for women facing this aggressive cancer.
Prof. Dr. Takuma Hayashi’s research primarily focuses on molecular oncology and infectious diseases, particularly cancer biomarkers and viral infections. 🧬🔬 His work on uterine leiomyosarcoma involves discovering key diagnostic biomarkers like LMP2 to improve early detection and treatment strategies in aggressive cancers. 🩺🎗️ Additionally, Dr. Hayashi explores infectious diseases such as avian influenza and COVID-19, emphasizing the One Health approach to prevent viral spread between animals and humans. 🦠🌍 His interdisciplinary research bridges cancer biology, immunology, and public health, aiming to develop precision medicine therapies and enhance global disease control efforts.
THE ROLE OF LIVE BIRD MARKETS SHOULD BE EMPHASIZED IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA INFECTIONS
THE IMPORTANCE OF ONE HEALTH IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA/H5N1
Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer
DEVELOPMENT OF ENDOSALPINGIOSIS IN PATIENTS WITH A HISTORY OF BREAST CANCER
High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study
POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY
Dr. Xin Huang’s academic journey commenced at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, where their dedication to medical and research excellence became evident. Since September 2017, Dr. Huang has pursued a dual degree (M.D., Ph.D.), focusing on the nexus of clinical medicine and groundbreaking research. This rigorous training honed both clinical acumen and investigative prowess, laying the foundation for significant contributions to medical science. Their education encompassed advanced studies in bone and joint diseases, immune inflammation, and regenerative medicine, highlighting a strong commitment to tackling some of the most pressing challenges in healthcare.
Dr. Xin Huang is currently an Attending Doctor at Union Hospital, Tongji Medical College. In this capacity, they seamlessly integrate patient care with research innovation. Beyond clinical practice, Dr. Huang has contributed to over 38 peer-reviewed publications in high-impact journals, reflecting a commitment to advancing medical knowledge.
Their professional engagements also include editorial roles on the Young Editorial Boards of journals like iMeta, Biomaterials Translational, and Gene Expression. These roles underscore their expertise and standing in the scientific community. Furthermore, Dr. Huang has expanded their horizons internationally through a visiting study at the University of Würzburg, Germany, fostering global collaboration in cutting-edge research.
Dr. Huang’s research portfolio is both diverse and impactful. Their primary focus lies in targeted and precise treatment of bone tumors, particularly through an innovative approach centered on the tumor microenvironment (TME). Key areas of research include:
This work has contributed to new paradigms in treating bone tumors and has significant implications for broader applications in oncology, regenerative medicine, and immunology.
Dr. Xin Huang’s dedication to research and patient care has been widely recognized. With 38 SCI/Scopus-indexed publications and three patents, Dr. Huang has firmly established themselves as a thought leader in their field. Their editorial appointments and membership in prestigious organizations such as the Chinese Medical Doctor Association and the Tumor Precision Therapy Professional Committee of the Chinese Anti-Cancer Association further attest to their standing in the academic and medical community.
Notably, Dr. Huang is a nominee for the Best Researcher Award, a testament to their relentless pursuit of excellence and innovation.
Dr. Huang’s work transcends academic circles, offering tangible benefits for patients and practitioners alike. By revealing the intricacies of the tumor microenvironment and advancing targeted treatments, they have paved the way for more effective therapies with fewer side effects.
Their contributions have also fostered international collaboration, bridging the gap between research communities in China and Europe. As an advocate for interdisciplinary research, Dr. Huang’s efforts have influenced emerging areas such as nanomedicine, tissue engineering, and immune-oncology.
Dr. Xin Huang’s legacy is one of innovation, compassion, and collaboration. As they continue their work in regenerative medicine and oncology, their future goals include:
In summary, Dr. Xin Huang’s journey is characterized by a commitment to excellence in medicine and science. Through their pioneering research, professional dedication, and collaborative spirit, they are poised to leave an enduring impact on the fields of oncology, regenerative medicine, and beyond.
The foundation of this individual’s career is rooted in a strong academic background. Although specific details about early education are not mentioned, the advanced roles undertaken in both pharmaceutical and medical sectors suggest a deep understanding and expertise in pharmacology, clinical pharmacy, and sterile medication preparation. Their professional journey likely began with formal education in pharmacy, complemented by continuous professional development and specialized training. The fact that they were entrusted with high-responsibility roles, such as acting pharmacy director, regulatory manager, and clinical instructor, indicates a robust educational foundation coupled with a commitment to lifelong learning.
Their association with the SAAD Training Institute, affiliated with Duke University, is an important academic highlight. This affiliation points to their exposure to global standards in pharmaceutical education and practices, which undoubtedly shaped their approach to teaching and developing competencies within their professional network.
SAAD Specialist Hospital, Saudi Arabia (Dec 2003 – Jun 2006)
This phase of the career showcases the breadth and depth of their professional experience in Saudi Arabia’s healthcare system, particularly within SAAD Specialist Hospital, a prominent medical institution. Initially starting as a Pediatric Clinical Pharmacist in 2003, they quickly rose through the ranks to take on more senior and specialized roles.
These roles reflect a strong command over clinical pharmacy, sterile practices, and pharmaceutical education, making them a critical contributor to healthcare improvement in Saudi Arabia.
Governmental Hospital of Tropical Diseases, Ministry of Health, Egypt (Dec 1997 – Dec 2003)
Their role at this governmental hospital in Egypt demonstrates significant leadership and management skills within the pharmaceutical services sector.
This progression in Egypt’s healthcare sector speaks to their competence, leadership abilities, and the trust placed in them to manage essential healthcare operations.
CBIC Medical, Pharmaceutical Development, and Consultation Company (Nov 2002 – Dec 2003)
In parallel with their role in Egypt’s healthcare system, they also held a position in CBIC Medical, which involved regulatory and marketing responsibilities in the pharmaceutical sector.
This role illustrates their ability to work across both clinical and commercial spheres, bridging the gap between product development, regulatory compliance, and market outreach.
While explicit research endeavors are not mentioned, their extensive work in teaching, sterile medication preparation, and regulatory roles highlights a career deeply rooted in evidence-based practices. Their focus on educating healthcare professionals in critical areas like aseptic techniques and sterile medication preparation indicates a dedication to improving healthcare outcomes through rigorous training.
The supervisory roles in sterile medication preparation, particularly for vulnerable populations such as neonates and pediatric patients, point to a keen interest in precision pharmacy and patient safety, areas likely to have been influenced by research in clinical pharmacology.
The trust and leadership roles assigned to them—ranging from being an Acting Pharmacy Director to a supervisor and instructor at the SAAD Specialist Hospital—reflect the high regard in which they were held by their peers and employers. Their instructional role at the SAAD Training Institute, affiliated with Duke University, is a significant marker of their expertise and the recognition they received in the field of pharmaceutical education.
Their influence spans multiple facets of healthcare, particularly in the realms of education, clinical pharmacy, and sterile medication practices. Through teaching roles, both at SAAD and CBIC Medical, they shaped the competencies of numerous healthcare professionals, directly impacting patient safety and care quality.
As a supervisor in the preparation of sterile medications, they ensured that some of the most vulnerable patients—neonates and those undergoing chemotherapy—received safe, effective treatments. This role would have had a profound impact on patient outcomes, underscoring their influence in clinical settings.
Their legacy is marked by the high standards of training and education they provided, particularly in aseptic techniques and sterile medication preparation. The knowledge they imparted to medical representatives and pharmacy staff will continue to influence healthcare practices long after their direct involvement.
Long Pang was born in Gansu, China, where he developed an early passion for science and innovation. His academic journey began with a focus on veterinary science, where he pursued a Master of Science (M.S.) degree at Northwest Agricultural and Forestry University in Yangling, Shaanxi, China. Completing his M.S. in July 2012, Pang demonstrated an exceptional commitment to his studies and research in veterinary science, laying the groundwork for his future endeavors in animal biotechnology. In August 2012, he advanced his academic career by enrolling in a Ph.D. program at the same university. During his Ph.D. studies, he specialized in Animal Biotechnology, a field that encompasses the use of biotechnological tools for the improvement of animal health and productivity. He completed his Ph.D. in July 2016, marking the beginning of a promising career in biomedical research.
After earning his Ph.D., Long Pang joined Xi’an Medical University as an Associate Professor in the School of Basic Medical Science. His professional career is distinguished by his innovative research in the areas of microfluidics and single-cell analysis. At Xi’an Medical University, Pang quickly established himself as a leading researcher, focusing on the development of microfluidic chips and their applications in single-cell analysis and organ-on-a-chip technology. His work has been instrumental in advancing the understanding of cellular mechanics and tumor microenvironments, contributing significantly to the fields of biomedical engineering and cancer research.
Long Pang’s research primarily revolves around microfluidics-based single-cell analysis and organ-on-a-chip technologies. His work has led to the development of innovative microfluidic devices that allow for the manipulation and analysis of single cells in a highly controlled environment. These devices have broad applications in cancer research, particularly in studying tumor microenvironments and the behavior of cancer stem cells. One of his significant contributions includes the development of a microfluidic chip for glioma stem cell sorting and single-cell-derived tumor sphere assays. This research has provided valuable insights into the formation of tumor spheres and the role of the tumor microenvironment in cancer progression.
Pang has also been involved in projects aimed at integrating microfluidic platforms with other technologies to enhance the precision and efficiency of single-cell analysis. His research has been supported by several prestigious grants, including those from the National Science Foundation of China and the Fundamental Research Foundation of Xi’an Medical University. Notably, he has led projects such as the study of heterotypic single-cell-derived tumor-sphere formation using an integrated microfluidics platform, which has garnered significant attention and funding.
Long Pang’s contributions to the field of biomedical research have been widely recognized. His work has resulted in over 21 publications in high-impact journals, including TRAC-Trends in Analytical Chemistry, Analytical Chemistry, and Sensors & Actuators B: Chemical. He has also authored a chapter in the Handbook of Single-Cell Technologies, published by Springer, highlighting his expertise in digital microfluidics for single-cell manipulation and analysis. In addition to his publications, Pang has been granted two Chinese patents related to his innovations in microfluidic technology, further establishing his reputation as a leading researcher in his field.
Pang’s achievements have also been acknowledged through various editorial appointments. He has served as a Youth Editorial Board Member of Glioma and the E-Journal of Translational Medicine, where he has contributed to the advancement of research dissemination and knowledge sharing in the scientific community. His contributions to the academic community extend beyond research, as he is an active member of several professional organizations, including the Shaanxi Pharmacology Association, the Chinese Society of Micro-Nano Technology (CSMNT), and the Chinese Chemistry Society (CCS).
The impact of Long Pang’s research extends beyond academia. His work on microfluidic devices has the potential to revolutionize the way single-cell analysis is conducted, offering new tools for researchers and clinicians in the diagnosis and treatment of diseases, particularly cancer. His contributions to the development of organ-on-a-chip technology are also significant, providing a platform for more accurate and efficient drug testing, which could lead to more effective treatments for various diseases.
Pang’s research has influenced a new generation of scientists and engineers, inspiring them to explore the possibilities of microfluidics and its applications in biomedical research. His collaborations with other leading researchers and institutions, both in China and internationally, have further expanded the reach of his work, fostering innovation and knowledge exchange in the global scientific community.
Long Pang’s legacy in the field of biomedical research is characterized by his innovative approach to solving complex problems in cell biology and medicine. His contributions to the development of microfluidic technology and single-cell analysis tools have set new standards in the field, paving the way for future research and innovation. As he continues his work at Xi’an Medical University, Pang remains committed to advancing the frontiers of biomedical engineering, with a focus on developing new technologies that can improve human health and well-being.
Looking to the future, Long Pang’s ongoing research projects, such as the construction of a 3D microenvironment for single-cell level tumor cells, promise to yield further breakthroughs in our understanding of cancer and other diseases. His work is likely to continue to influence the field for years to come, as he mentors the next generation of researchers and contributes to the global effort to improve healthcare through technological innovation.